IOBT - IO Biotech to Present at 44th Annual Cowen Health Care Conference | Benzinga
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, announced today that Mai-Britt Zocca, Ph.D., the company's President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company's CFO, will be participating in one-on-one investor meetings at the 44th Annual Cowen Health Care Conference to be held March 4-6, 2024 in Boston, MA.
Presentation Details
Date and Time: Wednesday, March 6, 2024, 12:50-1:20 PM EST
Presenter: Mai-Britt Zocca, Ph.D., President & CEO
Webcast Link: https://wsw.com/webcast/cowen154/iobt/2016052
A webcast replay of the presentation will be available from the Investors section of the Company's website at www.iobiotech.com for 90 days.
About IO102-IO103
IO102-IO103 is an investigational therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by stimulating activation and expansion of T cells against indoleamine 2,3-dioxygenase (IDO) and/or programmed death-ligand 1 (PD-L1) cells. The company is currently conducting a pivotal Phase 3 trial (IOB-013/KN-D18; NCT05155254) investigating IO102-IO103 in combination with pembrolizumab versus pembrolizumab ...